WO1999006438A3 - Compounds with anti-ks and anti-hiv activity - Google Patents

Compounds with anti-ks and anti-hiv activity Download PDF

Info

Publication number
WO1999006438A3
WO1999006438A3 PCT/CA1998/000731 CA9800731W WO9906438A3 WO 1999006438 A3 WO1999006438 A3 WO 1999006438A3 CA 9800731 W CA9800731 W CA 9800731W WO 9906438 A3 WO9906438 A3 WO 9906438A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
fragments
hiv
hcg
kaposi
Prior art date
Application number
PCT/CA1998/000731
Other languages
French (fr)
Other versions
WO1999006438A2 (en
Inventor
Tony Antakly
Ram M Sairam
Original Assignee
Univ Montreal
Tony Antakly
Ram M Sairam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal, Tony Antakly, Ram M Sairam filed Critical Univ Montreal
Priority to AU85261/98A priority Critical patent/AU8526198A/en
Priority to CA002299054A priority patent/CA2299054A1/en
Priority to EP98936050A priority patent/EP1017722A2/en
Publication of WO1999006438A2 publication Critical patent/WO1999006438A2/en
Publication of WO1999006438A3 publication Critical patent/WO1999006438A3/en
Priority to US09/494,500 priority patent/US6683050B1/en
Priority to US10/733,323 priority patent/US20040253608A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a compound having anti-KS and anti-HIV pharmaceutical activity which comprises an HCG-like inhibitory protein and fragments or derivatives thereof, said protein and fragments thereof are isolated from a biologically active fraction of APL-HCG, wherein said protein has a molecular weight of about 3,500 or of about 13,000 Dalton, and wherein said protein and fragments thereof are adsorbed polypropylene plastic supports. A pharmaceutical composition for the prevention and/or treatment of Kaposi's sarcoma (KS) and HIV which comprises a therapeutically effective amount of at least one compound of the present invention in association with a pharmaceutically acceptable carrier. A method for the prevention, treatment and/or reduction of Kaposi's sarcoma and HIV expression in AIDS patients, which consists in administering the composition to the patient.
PCT/CA1998/000731 1997-08-01 1998-07-30 Compounds with anti-ks and anti-hiv activity WO1999006438A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU85261/98A AU8526198A (en) 1997-08-01 1998-07-30 Compounds with anti-ks and anti-hiv activity
CA002299054A CA2299054A1 (en) 1997-08-01 1998-07-30 Compounds with anti-ks and anti-hiv activity
EP98936050A EP1017722A2 (en) 1997-08-01 1998-07-30 Compounds with anti-ks and anti-hiv activity
US09/494,500 US6683050B1 (en) 1997-08-01 2000-01-31 Compounds with anti-KS and anti-HIV activity
US10/733,323 US20040253608A1 (en) 1997-08-01 2003-12-12 Compounds with anti-KS and anti-HIV activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5454397P 1997-08-01 1997-08-01
US60/054,543 1997-08-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/494,500 Continuation US6683050B1 (en) 1997-08-01 2000-01-31 Compounds with anti-KS and anti-HIV activity

Publications (2)

Publication Number Publication Date
WO1999006438A2 WO1999006438A2 (en) 1999-02-11
WO1999006438A3 true WO1999006438A3 (en) 1999-04-08

Family

ID=21991839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000731 WO1999006438A2 (en) 1997-08-01 1998-07-30 Compounds with anti-ks and anti-hiv activity

Country Status (5)

Country Link
EP (1) EP1017722A2 (en)
CN (1) CN1271365A (en)
AU (1) AU8526198A (en)
CA (1) CA2299054A1 (en)
WO (1) WO1999006438A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
CN105698714B (en) * 2016-02-26 2018-09-25 江汉大学 Motion scan tunnel drift section and volume measurement device and its measurement method

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713366A (en) * 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
WO1989008663A1 (en) * 1988-03-17 1989-09-21 Mayo Foundation For Medical Education And Research Synthetic peptides derived from the alpha-subunit of human glycoprotein hormones
WO1992005447A1 (en) * 1990-09-21 1992-04-02 The Salk Institute For Biological Studies FUNCTIONAL ANTAGONISM BETWEEN PROTO-ONCOPROTEIN c-JUN AND HORMONE RECEPTORS
WO1996004008A1 (en) * 1994-08-05 1996-02-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
WO1996010412A1 (en) * 1994-10-04 1996-04-11 Harris Pamela J Use of human chorionic gonadotropin as an immune-potentiating agent
WO1996030505A1 (en) * 1995-03-27 1996-10-03 The Regents Of The University Of California Methods for screening compounds for estrogenic activity
WO1997014428A1 (en) * 1995-10-16 1997-04-24 Applied Research Systems Use of human chorionic gonadotropin in the treatment of kaposi's sarcoma
WO1997049432A1 (en) * 1996-06-24 1997-12-31 University Of Maryland Biotechnology Institute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713366A (en) * 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
WO1989008663A1 (en) * 1988-03-17 1989-09-21 Mayo Foundation For Medical Education And Research Synthetic peptides derived from the alpha-subunit of human glycoprotein hormones
WO1992005447A1 (en) * 1990-09-21 1992-04-02 The Salk Institute For Biological Studies FUNCTIONAL ANTAGONISM BETWEEN PROTO-ONCOPROTEIN c-JUN AND HORMONE RECEPTORS
WO1996004008A1 (en) * 1994-08-05 1996-02-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
WO1996010412A1 (en) * 1994-10-04 1996-04-11 Harris Pamela J Use of human chorionic gonadotropin as an immune-potentiating agent
WO1996030505A1 (en) * 1995-03-27 1996-10-03 The Regents Of The University Of California Methods for screening compounds for estrogenic activity
WO1997014428A1 (en) * 1995-10-16 1997-04-24 Applied Research Systems Use of human chorionic gonadotropin in the treatment of kaposi's sarcoma
WO1997049432A1 (en) * 1996-06-24 1997-12-31 University Of Maryland Biotechnology Institute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KACHRA Z. ET AL.: "Low molecular weight compounds but not dimeric hCG inhibit growth and down-regulate AP-1 transcription factor in Kaposi's sarcoma cells", ENDOCRINOLOGY, vol. 138, no. 9, September 1997 (1997-09-01), BETHESDA US, pages 4038 - 4041, XP002090808 *
LUNARDI-ISKANDAR Y ET AL: "TUMORIGENESIS AND METASTASIS OF NEOPLASTIC KAPOSI S SARCOMA CELL LINE IN IMMUNODEFICIENT MICE BLOCKED BY A HUMAN PREGNANCY HORMONE", NATURE., vol. 375, 4 May 1995 (1995-05-04), LONDON GB, pages 64 - 68, XP002023439 *
LUNARDI-ISKANDER Y. ET AL.: "Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease", NATURE MEDICINE., vol. 4, no. 4, April 1998 (1998-04-01), NEW YORK US, pages 428 - 434, XP002090807 *
T HOPP: "Human chorionic gonadotropin hoodwinks Gallo", NATURE BIOTECHNOLOGY., vol. 15, September 1997 (1997-09-01), UBLISHING US, pages 834 - 835, XP002090806 *

Also Published As

Publication number Publication date
AU8526198A (en) 1999-02-22
CA2299054A1 (en) 1999-02-11
EP1017722A2 (en) 2000-07-12
WO1999006438A2 (en) 1999-02-11
CN1271365A (en) 2000-10-25

Similar Documents

Publication Publication Date Title
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
NO911854D0 (en) PROCEDURE FOR THE PREPARATION OF PEPTID DERIVATIVES.
SG49625A1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
AU2905092A (en) Pharmaceutical dipeptide compositions and methods of use thereof
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
BG101118A (en) Therapeutical compounds
CA2139385A1 (en) Products containing g-csf and tnf binding protein
NZ514558A (en) Viral treatment
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
JP2002523437A5 (en)
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
WO1999061014A3 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
WO1999006438A3 (en) Compounds with anti-ks and anti-hiv activity
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
EP0744176A3 (en) Methods for inhibiting bone loss
IE892261L (en) Therapeutic compounds
WO1997017072A3 (en) Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
CA2221793A1 (en) Novel antibacterial protein
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
WO1999038524A3 (en) Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98809398.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2299054

Country of ref document: CA

Ref document number: 2299054

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09494500

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998936050

Country of ref document: EP

712F Gb: determination of foreign entitlement (section 12(1)/1977)
713D Gb: proceedings under sect. 13(1) pat. act 1977 ** application filed
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998936050

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936050

Country of ref document: EP